The Union Health Ministry has issued a formal directive to all states and Union Territories, mandating strict adherence to regulatory standards regarding **stem cell therapy**. This move follows growing concerns over the proliferation of unauthorized clinics promising curative outcomes for conditions that currently lack clinical validation.
Health officials have emphasized that **stem cell research** and clinical applications must strictly follow the **National Guidelines for Stem Cell Research (NGSCR)**. These protocols, established by the **Indian Council of Medical Research (ICMR)** and the **Department of Biotechnology (DBT)**, are designed to ensure patient safety and ethical practice.
The ministry has expressed alarm over private establishments advertising **regenerative medicine** for disorders such as autism, cerebral palsy, and various neurodegenerative diseases. According to regulatory experts, there is currently no approved **stem cell-based product** in the country for the treatment of these conditions outside of strictly monitored clinical trials.
State authorities are now required to conduct rigorous audits of all healthcare facilities offering such services. The directive explicitly warns that any facility operating without proper clearance from the **Central Drugs Standard Control Organization (CDSCO)** will face immediate legal action. Furthermore, state medical councils have been instructed to investigate practitioner advertisements that make exaggerated or unsubstantiated medical claims.
For patients and their families, this directive serves as a crucial warning. Medical experts urge the public to verify whether a facility has received institutional ethics committee approval and whether the proposed treatment is backed by peer-reviewed, evidence-based data. Engaging in unproven **cell-based therapies** carries significant health risks, including immune rejection, tumor formation, and severe secondary infections.
As the government tightens oversight, the focus remains on curbing the “medical tourism” of unverified procedures. The health department has requested that district-level administrators prioritize the monitoring of clinics that lack accredited **Good Manufacturing Practice (GMP)** facilities.
This regulatory crackdown marks a significant step toward safeguarding public health. By enforcing these mandates, the government aims to prevent the exploitation of vulnerable patients while fostering a legitimate environment for genuine **biotechnology** innovation. Healthcare providers are advised to review their clinical protocols immediately to ensure full compliance with the updated government directives.
